Source: CNBC Journey Medical Corporation, a subsidiary of Fortress Biotech, Inc. (FBIO), launched the first two prescription products in its dermatology franchise, Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion. Both products will be showcased at the 2016 American Academy of Dermatology (AAD) Summer Meeting (Booth #622) to be held…...
Valeant’s Ex-CEO Michael Pearson Sells Nearly $100 Million in Company Stock
Source: The Wall Street Journal Michael Pearson has sold nearly $100 million of his stock in Valeant Pharmaceuticals International Inc. in the past two weeks, according to securities filings, following his firing as the troubled drugmaker’s chief executive in March. Mr. Pearson sold 288,441 shares on June 30 for $5.8…...
Galderma Announces FDA Approval of Full Prescription-Strength Differin® Gel For Over-the-Counter Acne Use
Source: Galderma, a global leader focused on medical solutions in skin health, today announced that its U.S. affiliate, Galderma Laboratories, L.P. received approval from the U.S. Food and Drug Administration (FDA) for Differin® Gel (adapalene gel 0.1%) as an over-the-counter (OTC) treatment for acne. This approval makes Differin® Gel the…...
LEO buys rights to AstraZeneca’s skin drug
Source: LEO Pharma has entered a strategic partnership with AstraZeneca for new medicines for atopic dermatitis and psoriasis, major skin diseases with a significant unmet medical need. Under the move, LEO gains a the global licence to AZ' tralokinumab in skin diseases and an exclusive licence to brodalumab in Europe.…...